Purpose of reviewThe platelet surface harbors a lush forest of glycans (carbohydrate polymers) attached to membrane proteins and lipids. Accumulating evidence suggests that these glycans may be relevant to the pathophysiology of immune thrombocytopenia (ITP). Here, we critically evaluate data that point to a possible role for loss of sialic acid in driving platelet clearance in ITP, comment on the potential use of neuraminidase inhibitors for treatment of ITP, and highlight open questions in this area.Recent findingsMultiple lines of evidence suggest a role for loss of platelet sialic acid in the pathophysiology of thrombocytopenia. Recent work has tested the hypothesis that neuraminidase-mediated cleavage of platelet sialic acid may trigger clearance of platelets in ITP. Some clinical evidence supports efficacy of the viral neuraminidase inhibitor oseltamivir in ITP, which is surprising given its lack of activity against human neuraminidases.SummaryFurther study of platelet glycobiology in ITP is necessary to fill key knowledge gaps. A deeper understanding of the roles of platelet glycans in ITP pathophysiology will help to guide development of novel therapies.
CITATION STYLE
Tiemeyer, K. H., Kuter, D. J., Cairo, C. W., & Hollenhorst, M. A. (2023, November 1). New insights into the glycobiology of immune thrombocytopenia. Current Opinion in Hematology. Lippincott Williams and Wilkins. https://doi.org/10.1097/MOH.0000000000000781
Mendeley helps you to discover research relevant for your work.